Thank you for sharing!

Your article was successfully shared with the contacts you provided.
San Jose-based Calpine Corp. completed financing for the construction of a new 300-megawatt power plant, snaring $150 million in financing from a group of banks to build the new plant. Latham & Watkins partner John Kenney led the team representing the lead lender, Credit Lyonnais, in the financing arrangement. Kenney is in the firm’s San Francisco office. Led by partner David Spielberg, attorneys in the San Francisco office of Stoel Rives represented Calpine. The company has been working to complete the plant, called the Blue Spruce Energy Station, for two years. It is expected to be fully operational in May. “There’s usually one big thing that goes wrong in a transaction like this,” said Latham’s Kenney. “But David Spielberg and I go back over 15 years — we didn’t have to waste a lot of time and it was well executed. Everyone worked well together.” The plant, east of Denver, will provide extra power to Colorado during peak operating hours. Calpine will sell the output of the plant to Public Service Co. of Colorado. In addition to Kenney, Latham & Watkins San Francisco based associates Rowland Cheng and Erik Langner worked on the deal. San Diego-based partner Joel Mack and associate Elizabeth Cason also worked on the transaction. Partner David Schwartz and associate David Tewksbury worked out of the firm’s Washington, D.C., office. In addition to Spielberg in Stoel Rives’ San Francisco office, partner Henrik Perry Taubman and associates Kristin Nelson and Philip van Aelstyn assisted in representing Calpine. The Colorado-based law firm of Davis Graham & Stubbs handled permitting and real estate issues within Colorado for Calpine. The Washington, D.C., office of Davis Wright Tremaine handled federal regulatory matters. ISTA PHARMACEUTICALS Attorneys in the East Palo Alto office of Brobeck, Phleger & Harrison represented ISTA Pharmaceuticals Inc. through a $40 million equity capital deal. The ISTA investors included in the equity transaction are the Sprout Group, Sanderling Venture Partners and Investor Growth Capital. ISTA develops proprietary therapeutic products for improving eyesight. Brobeck partner Warren Lazarow led the deal. In addition, partner Rod Howard and associates Jonathan Gilliland and Sam Zucker worked on the deal.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.